Jaguar Health, Inc. (JAGX): Depreciation & Amortization
$1.91M
Year ended 2025-12-31
$1.90M
Trailing 12 months to 2026-06-30
-1.2%
3-year compound annual growth
+2.1%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.91M | +0.7% | 2026-04-07, From 2025-01-01 |
| 2024-12-31 | $1.90M | -5.6% | 2026-04-07, From 2024-01-01 |
| 2023-12-31 | $2.01M | +1.6% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $1.98M | +15.2% | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | $1.72M | -0.5% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $1.73M | -0.6% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $1.74M | +31.7% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $1.32M | +125.7% | 2020-04-03, From 2018-01-01 |
| 2017-12-31 | $584.3K | n/m | 2019-04-10, From 2017-01-01 |
| 2016-12-31 | $47.5K | +821.3% | 2018-04-09, From 2016-01-01 |
| 2015-12-31 | $5.2K | n/a | 2017-02-15, From 2015-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $1.91M | +0.7% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $1.71M | -3.4% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $39.0K | +77.3% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $600.0K | +20.0% |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $1.90M | -34.5% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $3.20M | -29.3% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $895.0K | +0.2% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $192.0K | -42.5% |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $4.51M | +51.3% |
Compare JAGX, PRLD, EMMA, EVMN side by side · Screen every company in Pharmaceutical Preparations ↗